Jhpiego has been supporting efforts to prevent malaria in pregnancy (MiP) in over 30 countries since 2001.
Why are pregnant women at risk of malaria?
Pregnancy reduces a woman’s immunity to malaria, which makes her more susceptible to malaria infection and increases her risk of illness. In pregnant women, malaria can lead to severe anemia, spontaneous abortion (miscarriage), stillbirth, premature delivery, delivery of low-birthweight babies, and death. Women in their first pregnancy are most at risk. Parasites can be present in the placenta and contribute to maternal anemia even when the mother does not appear to be ill. The use of intermittent preventive treatment in pregnancy (IPTp) reduces these risks and should be part of routine antenatal care in moderate and high transmission areas.
How We Make an Impact
Our support is in line with the WHO-recommended three-pronged approach to the prevention of malaria during pregnancy:
- Insecticide-treated nets
- Intermittent preventive treatment
- Effective case management of malarial illness
In 2017, Jhpiego supported programs in 16 countries and reached:
- 3,500,000 pregnant women with preventive treatment
- 1,500,000 pregnant women with two or more doses of IPTp
- 967 deaths
- 81,500 years lost to ill health, disability or early death
Transforming Intermittent Preventive Treatment for Optimal Pregnancy (TIPTOP) is Jhpiego’s new, innovative community-based approach to ensure pregnant women in malaria-affected countries in sub-Saharan Africa receive preventive treatment services.
Maternal and Child Survival Program (MCSP)
MCSP supports MIP programming through a core set of interventions that help to strengthen health systems, build capacity, and sustain results—across the continuum of care—resulting in high-quality MIP services.